OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.

Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Publication Speed (median values for papers published in 2023): Submission to First Decision: 5.7 weeks; Submission to Acceptance: 17.9 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017

Special Issue

Research on Neurodegenerative Diseases

Submission Deadline: December 15, 2020 (Open) Submit Now

Guest Editor

Douglas G. Walker, PhD

Special Contract Professor, Molecular Neuroscience Research Center, Shiga University of Medical Science, Otsu 520-2192, Japan


Research Interests: Alzheimer’s disease; Parkinson’s disease; neurodegenerative diseases

About This Topic

It is with pleasure that we are inviting submissions for this special issue entitled “Research on Neurodegenerative Diseases”. This is a broad title but it is timely for researchers to discuss their hypotheses, results and reviews on the current state of the field with emphasis on new research approaches. Neurodegenerative diseases remain one of the most significant causes of morbidity and mortality, particularly in the aging populations. Despite years of biological and medical research, there are still an unfilled need for new and effective therapies for diseases such as Alzheimer’s disease, Parkinson’s disease, Dementia with Lewy bodies, stroke, vascular dementia and multiple sclerosis. It is timely to consider whether current targets such as amyloid beta, tau, inflammation, alpha synuclein amongst others need to be reconsidered, and whether immunotherapy is likely to be effective. With the huge increase in RNA expression and single nucleotide polymorphism data, consideration how these data have advanced therapy development is also warranted. Similarly, there is a need to consider how the use of induced pluripotent stem cells has advanced our understanding of neurodegeneration.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (geriatrics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!


Open Access Research Article

Study of the Development of Carotid Artery Atherosclerosis upon Oxidative Stress using Infrared Spectroscopy and Scanning Electron Microscopy

Received: 07 March 2021;  Published: 12 October 2021;  doi: 10.21926/obm.geriatr.2104180


In the present study, Fourier-transform infrared (FTIR) spectroscopy and Scanning Electron Microscopy (SEM) were used to investigate the formation and development of carotid artery atherosclerosis. The FTIR spectra showed that with the progression of atheromatic plaque formation, the collagen changed its native structure from [...]
Open Access Review

Regulation of Membrane Phospholipid Homeostasis in Neurodegenerative Diseases

Received: 21 December 2020;  Published: 21 July 2021;  doi: 10.21926/obm.geriatr.2103176


Neurodegenerative diseases (NDs) are a diverse group of neuropathological diseases that are currently incurable due to the irreversible neuronal loss. At the present rate of the world population growth, it is projected that the number of ND cases will double by the year of 2050. With treatments only available for symptom management [...]
Open Access Review

Deep Brain Stimulation – Therapeutic Possibilities in Alzheimer's Disease

Received: 02 December 2020;  Published: 30 April 2021;  doi: 10.21926/obm.geriatr.2102170


Alzheimer’s Disease (AD) is the leading cause of dementia worldwide, and represents a significant cause of cognitive decline, disability, and mortality. Ongoing clinical trials continue to investigate β-amyloid targeted therapy with unclear benefit, and we are currently limited to symptomatic treatment. Therefore, there is a [...]
Open Access Original Research

Molecular Basis of Allogeneic Pluripotent Stem Cell Treatment of a Patient with Sporadic ALS

Received: 21 August 2020;  Published: 29 March 2021;  doi: 10.21926/obm.geriatr.2101164


There are no curative strategies for ALS, and as a result the alternative therapies are gaining ground, in particular the stem cell-based therapies which hold a promising future. Here we describe an ALS patient, who by choice, received allogeneic human cord-blood derived multipotent stem cells (MSC) intravenously and intrathecally. This is [...]
Open Access Research Article

Post-mortem 7.0-Tesla Magnetic Resonance Imaging of the Hippocampus in Amyotrophic Lateral Sclerosis

Received: 12 October 2020;  Published: 17 December 2020;  doi: 10.21926/obm.geriatr.2004143


Amyotrophic lateral sclerosis (ALS) is reported to be probably linked to frontotemporal lobar degeneration (FTLD). Since FTLD is characterized by severe frontotemporal degeneration along with hippocampal atrophy (HA), the present study used post-mortem 7.0-tesla magnetic resonance imaging to investigate whether a certain degree of HA occurs [...]